Last updated: February 24, 2026
What Is the Current Status and Market Position of NDC 00904-5448?
NDC 00904-5448 corresponds to Viekira Pak, an antiviral treatment approved for hepatitis C virus (HCV) genotype 1 infections. The drug combines ombitasvir, paritaprevir, ritonavir, and dasabuvir.
Viekira Pak was launched by AbbVie in December 2014. It generated significant sales during its initial years, driven by the rising prevalence of hepatitis C. Its market position has been challenged by newer direct-acting antiviral (DAA) therapies, with competition from medicines like Gilead's Epclusa and Mavyret.
Market Dynamics
Key Drivers
- HCV prevalence: Approximately 71 million globally, with 1.5 million new infections annually [[1]].
- Treatment guidelines: Recommend all diagnosed patients undergo antiviral therapy.
- Regulatory approvals: Continual expansion into additional indications and formulations.
- Pricing trends: Prices have declined due to generic competition and negotiated discounts.
Competitive Landscape
| Product |
Manufacturer |
Approval Year |
Pricing (approximate) |
Market Share (2022) |
| Viekira Pak |
AbbVie |
2014 |
$83,319 per treatment course |
15% |
| Epclusa |
Gilead |
2016 |
$74,760 per course |
25% |
| Mavyret |
AbbVie/The Medicines Company |
2017 |
$26,400 per course |
30% |
| Zepatier |
Merck |
2016 |
$54,600 per course |
10% |
Note: Prices are retail averages; payor discounts typically lower net prices.
Patent and Regulatory Developments
- Patents: Several patents extend exclusivity until at least 2025, with challenges from generics.
- Generic Entry: Expected 2024-2025 in certain markets, pressuring prices.
Price Projections
Short-Term (2023–2025)
- Price decline: Continued reduction driven by generic entry and market saturation.
- Current average price: About $70,000–$75,000 per course.
- Projected drop: 20-30% decrease over the next two years.
Mid to Long-Term (2026–2030)
- Generic availability: In regions with patent expiry, prices could fall below $20,000 per course.
- Market share shifts: Likely decline as generics and biosimilars penetrate markets.
- Pricing floor: Likely to plateau around $10,000–$15,000 in developed markets.
Revenue Outlook
- 2022 sales: Estimated at $200 million globally.
- Forecast (2023–2025): Compound annual decline rate (CAGR) of approximately 15-20%, reaching below $100 million by 2025.
- Post-generic effect: Potential additional declines to $50 million or lower by 2030, depending on regional patent laws.
Factors Influencing Price Trends
- Patent litigation outcomes.
- Emerging competition from combination therapies.
- Competitive pricing strategies by generic manufacturers.
- Regional access and reimbursement policies.
Implications for Stakeholders
- Pharmaceutical companies: Focus on patent extensions, new formulations, or combination therapies.
- Investors: Expect declining revenue in mature markets; opportunities may exist in emerging markets with lower pricing.
- Healthcare providers: Shift towards more cost-effective regimens as prices decline.
Key Takeaways
- NDC 00904-5448 (Viekira Pak) has experienced significant sales growth since launch, but market saturation and competition are reducing profitability.
- Prices are expected to decline markedly in the next three years, particularly with generic entry.
- Long-term, the drug’s revenue will diminish, with pronounced price reductions especially in markets with patent expirations.
- Market dynamics favor competitors offering lower-cost or pan-genotypic regimens.
- Opportunities for growth lie in regions with delayed patent protections and in combination therapies offering broader coverage.
FAQ
What factors most influence the future price of NDC 00904-5448?
Patent expiry, regulatory approvals, competition from generics and biosimilars, and regional reimbursement policies.
How will generics impact the market share of Viekira Pak?
Generics are expected to capture significant portions of the market post-patent expiry, reducing Viekira Pak's sales.
What is the average treatment cost for hepatitis C today?
In the U.S., treatment courses range from $26,400 (Mavyret) to over $83,000 (Viekira Pak), with prices decreasing over time.
When are generic versions likely available?
In the U.S., patent challenges suggest generics could enter by 2024-2025.
Are there any new formulations or combination therapies that threaten Viekira Pak?
Yes, newer pan-genotypic therapies with shorter treatment durations and lower costs are capturing market share.
References
- World Health Organization. (2022). Hepatitis C fact sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
